Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders

Clinical and Experimental Immunology

Volumn 187, Issue 2, 2017, Pages 304-315

  Wehling, C ^a   Amon, O ^b   Bommer, M ^c   Hoppe, B ^d   Kentouche, K ^e   Schalk, G ^f   Weimer, R ^g   Wiesener, M ^h   Hohenstein, B ⁱ   Tonshoff B ^j   Buscher R ^k   Fehrenbach, H ^l   Gok O N ^m   Kirschfink, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c ALB FILS Hospital Göppingen   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e JENA UNIVERSITY HOSPITAL   (Germany)

^f UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

^h UNIVERSITY HOSPITAL ERLANGEN   (Germany)

ⁱ UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^j UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^k UNIVERSITY HOSPITAL ESSEN   (Germany)

^l Institute of Pathology Hospital of Memmingen   (Germany)

^m UNIVERSITY OF FREIBURG   (Germany)

more..

Author keywords

biomarker; complement; drug monitoring; eculizumab; renal disease

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; ECULIZUMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE ANTIBODY MEDIATED RENAL GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT BLOOD LEVEL; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT FIXATION TEST; COMPLEMENT INHIBITION; COMPLEMENT MEDIATED RENAL DISORDER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULOPATHY; HEMOLYSIS ASSAY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; ID50; IMMUNOASSAY ANALYZER; KIDNEY CONCENTRATING CAPACITY; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MIDDLE AGED; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; SCHOOL CHILD; THROMBOCYTE COUNT; URINALYSIS; YOUNG ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ATYPICAL HEMOLYTIC UREMIC SYNDROME; DRUG EFFECTS; GLOMERULONEPHRITIS, MEMBRANOUS; GRAFT REJECTION; IMMUNOLOGY; INFANT; KIDNEY TRANSPLANTATION; METABOLISM;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BIOMARKERS; CHILD; CHILD, PRESCHOOL; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C5; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 85005915271     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12890     Document Type: Article

References (55)

1. Noris M, Remuzzi G. Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015. Am J Kidney Dis 2015; 66:359–75.
2. Zipfel PF, Skerka C, Chen Q et al. The role of complement in C3 glomerulopathy. Mol Immunol 2015; 67:21–30.
3. Nester CM, Brophy PD. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases. Curr Opin Pediatr 2013; 25:225–31.
4. Salvadori M, Rosso G, Bertoni E. Complement involvement in kidney diseases: from physiopathology to therapeutical targeting. World J Nephrol 2015; 4:169–84.
5. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8:643–57.
6. Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013; 56:199–212.
7. Barnett AN, Asgari E, Chowdhury P, Sacks SH, Dorling A, Mamode N. The use of eculizumab in renal transplantation. Clin Transplant 2013; 27:E216–29.
8. Barilla-Labarca ML, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol 2013; 148:313–21.
9. Pickering MC, Ismajli M, Condon MB et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology 2015; 54:2286–8.
10. Kelly RJ, Hill A, Arnold LM et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011; 117:6786–92.
11. Loschi M, Porcher R, Barraco F et al. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. Am J Hematol 2016; 91:366–70.
12. Rondelli T, Risitano AM, Peffault de Latour R et al. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica 2014; 99:262–6.
13. Nishimura J, Yamamoto M, Hayashi S et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med 2014; 370:632–9.
14. DeZern AE, Dorr D, Brodsky RA. Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Eur J Haematol 2013; 90:16–24.
15. Herlitz LC, Bomback AS, Markowitz GS et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 2012; 23:1229–37.
16. Kocak B, Arpali E, Demiralp E et al. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. Transplant Proc 2013; 45:1022–5.
17. Carr R, Cataland SR. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation. Ann Hematol 2013; 92:845–6.
18. Ardissino G, Testa S, Possenti I et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 2014; 64:633–7.
19. Nester C, Stewart Z, Myers D et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011; 6:1488–94.
20. Mayer MM. Complement and complement fixation. In: Kabat E, Mayer M, eds. Experimental immunochemistry. Springfield, IL: Charles C. Thomas, 1961:133–240.
21. Joiner KA, Hawiger A, Gelfand JA. A study of optimal reaction conditions for an assay of the human alternative complement pathway. Am J Clin Pathol 1983; 79:65–72.
22. Brandslund I, Siersted HC, Svehag SE, Teisner B. Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma. J Immunol Methods 1981; 44:63–71.
23. Rother U. A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. J Immunol Methods 1982; 51:101–7.
24. Mollnes TE, Lea T, Froland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985; 22:197–202.
25. Messias-Reason IJ, Hayashi SY, Nisihara RM, Kirschfink M. Complement activation in infective endocarditis: correlation with extracardiac manifestations and prognosis. Clin Exp Immunol 2002; 127:310–5.
26. Cugno M, Gualtierotti R, Possenti I et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014; 12:1440–8.
27. Habbig S, Bergmann C, Weber LT. Discontinuation of eculizumab in a patient with atypical hemolytic uremic syndrome due to a mutation in CFH. Am J Kidney Dis 2016; 67:532–3.
28. Volokhina EB, Westra D, van der Velden TJ, van de Kar NC, Mollnes TE, van den Heuvel LP. Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission. Clin Exp Immunol 2015; 181:306–13.
29. Noris M, Galbusera M, Gastoldi S et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014; 124:1715–26.
30. Schalk G, Kirschfink M, Wehling C et al. A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab. Pediatr Nephrol 2015; 30:1039–42.
31. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7:748–56.
32. Bomback AS. Eculizumab in the treatment of membranoproliferative glomerulonephritis. Nephron Clin Pract 2014; 128:270–6.
33. Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ. Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol 2013; 28:1975–81.
34. Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, Ricklin D, Lambris JD. Applying complement therapeutics to rare diseases. Clin Immunol 2015; 161:225–40.
35. Burwick RM, Burwick NR, Feinberg BB. Eculizumab fails to inhibit generation of C5a in vivo. Blood 2014; 124:3502–3.
36. Burwick RM, Burwick N, Feinberg BB. Response: maternal and cord C5a in response to eculizumab. Blood 2015; 126:279–80.
37. Volokhina EB, Bergseth G, van de Kar NC, van den Heuvel LP, Mollnes TE. Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo. Blood 2015; 126:278–9.
38. Amara U, Flierl MA, Rittirsch D et al. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185:5628–36.
39. Krisinger MJ, Goebeler V, Lu Z et al. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 2012; 120:1717–25.
40. Cofiell R, Kukreja A, Bedard K et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015; 125:3253–62.
41. Huber-Lang M, Sarma JV, Zetoune FS et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682–7.
42. Fridkis-Hareli M, Storek M, Mazsaroff I et al. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 2011; 118:4705–13.
43. Riedl M, Hofer J, Giner T et al. Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab. J Immunol Methods 2016; 435:60–7.
44. Bentall A, Tyan DB, Sequeira F et al. Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int 2014; 27:1235–43.
45. Wehling C, Kirschfink M. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis. J Thromb Haemost 2014; 12:1437–9.
46. Cullinan N, Gorman KM, Riordan M, Waldron M, Goodship TH, Awan A. Case report: benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome. Pediatrics 2015; 135:e1506–9.
47. Gatault P, Brachet G, Ternant D et al. Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule. MAbs 2015; 7:1205–11.
48. Fakhouri F, Fremeaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Eur J Intern Med 2013; 24:492–5.
49. Loirat C, Fakhouri F, Ariceta G et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016; 31:15–39.
50. Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C. Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol 2015; 30:775–81.
51. Volokhina EB, van de Kar NC, Bergseth G et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol 2015; 160:237–43.
52. Ruebner RL, Kaplan BS, Copelovitch L. A time for reappraisal of ‘atypical’ hemolytic uremic syndrome: should all patients be treated the same? Eur J Pediatr 2012; 171:1519–25.
53. Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transplant Proc 2012; 44:3037–40.
54. Peffault de Latour R, Fremeaux-Bacchi V, Porcher R et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 2015; 125:775–83.
55. Sheerin NS, Kavanagh D, Goodship TH, Johnson S. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM 2016; 109:27–33.